- New Rite Aid group VP pharmacy initiatives and clinical services to oversee Wellness Ambassador program
- Kathleen Sebelius cites pharmacists' importance as Rite Aid CEO introduces Obamacare resource program
- On the heels of Q3, Walgreens outlines shift in front-end strategy and pharmacy tailwinds looking forward
- Sandoz to market authorized generic version of Adderall XR
- Senate passes Drug Quality and Security Act
MORRISTOWN, N.J. — The Food and Drug Administration has approved a generic drug for attention deficit hyperactivity disorder made by Actavis, the drug maker said Monday.
Actavis, whose parent company was recently acquired by Watson Pharmaceuticals, announced the approval of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate extended-release capsules, also known as mixed-amphetamine salts ER capsules.
The drug, approved in the 5-mg, 10-mg, 15-mg, 20-mg, 25-mg and 30-mg strengths, is a generic version of Shire Adderall XR. The branded drug and generic versions had sales of $1.99 billion during the 12-month period ended in March, according to IMS Health.